Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN1 in Advanced Solid Tumor
NCT05038150Phase 2Recruiting
- Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Jan 2028
- Modality
- Oncolytic Bacteria, Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 2 trial of SGN1 in solid tumor, sponsored by Guangzhou Sinogen Pharmaceutical Co., Ltd.. Started Jan 2023; status: recruiting.
02
Drugs
SGN1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05038150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05038150.